Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Cardiovascular Impact of the New ArmoLIPID Cholesterol Plus Formulation: An In Silico Clinical Study Using 100,000 Digital Twins

NCT07892092 is registered in ClinicalTrials.gov with Aeterna Medical Solutions SL as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07892092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Cardiovascular Impact of the New ArmoLIPID Cholesterol Plus Formulation: An In Silico Clinical Study Using 100,000 Digital Twins
Lead sponsor
Aeterna Medical Solutions SL
Phase
Observational
Overall status
Completed
Start date
September 1, 2026
Completion date
October 14, 2026
Enrollment
100,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular risk, hypercholesterolemia

Arms

As registered; 3 arms.

  • Lifestyle Management (Reference Group)

    Synthetic digital twins receiving simulated standard lifestyle management, including dietary recommendations, regular physical activity, and cardiovascular risk factor management, without ArmoLIPID Cholesterol Plus supplementation. This group serves as the reference comparator for estimating long-term cardiovascular outcomes over 5, 10, 15, and 20 years.

  • Lifestyle Management + ArmoLIPID Cholesterol Plus

    Synthetic digital twins receiving simulated standard lifestyle management combined with one daily tablet of the new ArmoLIPID Cholesterol Plus formulation, without red yeast rice. The simulation estimates the long-term effects of LDL cholesterol (LDL-C) reduction on cumulative cardiovascular exposure and the projected incidence of major adverse cardiovascular events (MACE) over 5, 10, 15, and 20 years.

  • Exploratory Scenario - Enhanced LDL-C Reduction (Two Tablets Daily)

    Synthetic digital twins receiving simulated standard lifestyle management combined with two tablets daily of the new ArmoLIPID Cholesterol Plus formulation, without red yeast rice. This exploratory scenario assumes a sustained 32% reduction in LDL cholesterol (LDL-C) from baseline and evaluates its potential long-term impact on cumulative LDL-C exposure and the projected incidence of major adverse cardiovascular events (MACE) over 5, 10, 15, and 20 years. The assumed LDL-C reduction represents a hypothetical enhanced-response scenario and has not been clinically demonstrated for the two-tablet daily regimen. No human participants receive treatment in this simulation.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Projected Cumulative Incidence of First Major Adverse Cardiovascular Event (MACE) From simulation baseline to 5, 10, 15, and 20 years

    Estimation of the projected cumulative incidence of a first major adverse cardiovascular event (MACE), defined as the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, using the Aeterna Deep digital twin simulation platform. The outcome will be assessed across three simulated strategies: lifestyle management alone, lifestyle management combined with one daily tablet of the new ArmoLIPID Cholesterol Plus formulation, and an exploratory scenario involving two tablets daily with an assumed 32% LDL cholesterol LDL-C reduction. Cumulative event probabilities, absolute risk differences, and model-derived hazard ratios will be estimated at 5, 10, 15, and 20 years. All events are computationally projected and are not observed clinical events in human participants.

Lead sponsor's other trials

Aeterna Medical Solutions SL, most recent start first.

Similar trials

Same condition (Hypercholesterolemia) and phase, most recent start first.